FDA warns of pancreatitis risk in Byetta

Byetta, a diabetes drug jointly developed by Amylin Pharmaceuticals and Eli Lilly and Co., may be linked to acute pancreatitis in some patients, the FDA announced Tuesday. Patients who experience symptoms such as vomiting and persistent severe abdominal pain should be encouraged to seek immediate medical attention, the agency advised. Amylin said it will clarify warnings about acute pancreatitis to Byetta's label, and will send a letter to medical professionals about the issue.

View Full Article in:

Indianapolis Star (tiered subscription model), The · Globe and Mail (Toronto) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN